ABSTRACT OBJECTIVES This analysis reports on the initial German multicenter experience with the JenaValve (JenaValve Technology GmbH, Munich, Germany) transcatheter heart valve for the treatment of pure aortic regurgitation.
From April 12, 2012 through October 10, 2013, 31 patients were treated for pure aortic regurgitation using the JenaValve THV in 9
German centers (as listed in Online Table 1); early results on 5 of these patients were published before (9) . All patients presented with severe comorbidities precluding them from surgical aortic valve replacement as determined by an interdisciplinary heart team ( Table 1) . Pre-procedural workup was completed according to institutional standards. Evaluation and grading of aortic regurgitation at baseline was performed by transesophageal echocardiography in all patients (12) . Aortic annulus, root, and valve morphology were assessed by contrast-enhanced multi- Values are n, mean AE SD, n (%), n/N (%), or mean AE SD (n/n). *Previous valve surgery included mitral valve surgery (n ¼ 3) and aortic valve repair (n ¼ 3). †Ascending aorta diameters were assessed by multislice computed tomography or transesophageal echocardiography.
BMI ¼ body mass index; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; NYHA ¼ New York Heart Association; STS-PROM ¼ Society of Thoracic Surgeons Predicted Risk of Mortality.
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regurgitation in 28 of 31 patients. No more than mild regurgitation or signs of aortic stenosis were observed ( Figure 3A) .
30-DAY CLINICAL
OUTCOMES. According to the VARC-2 criteria (Table 3) Seiffert et al. Values are n, n (%), or mean AE SD. Thirty-day patient outcomes according to the updated Valve Academic Research Consortium definitions (14) . *Permanent pacemaker implantation for persistent sinus bradycardia (n ¼ 1) and complete heart block (n ¼ 1).
ICU ¼ intensive care unit; VARC ¼ Valve Academic Research Consortium.
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